Femasys receives FDA 510(k) clearance for FemChec fallopian tube diagnostic

FEMASYS INC

FemChec cleared by FDA for controlled contrast delivery to check tubal status.
FemChec is also used as confirmation test after FemBloc non-surgical permanent birth control.
FemBloc is in late-stage FINALE pivotal trial, currently enrolling.
FemChec uses natural contrast and ultrasound, avoiding x-ray dye and radiation exposure.
CEO Kathy Lee-Sepsick says clearance strengthens women's health product suite.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.